Viking Therapeutics (VKTX) vs. Its Rivals Head-To-Head Analysis

Viking Therapeutics (NASDAQ: VKTX) is one of 299 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Viking Therapeutics to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, dividends, valuation, earnings and risk.

Institutional and Insider Ownership

5.5% of Viking Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.2% of Viking Therapeutics shares are held by company insiders. Comparatively, 16.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Viking Therapeutics and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Viking Therapeutics N/A -$14.73 million -3.21
Viking Therapeutics Competitors $290.00 million $35.57 million 149.84

Viking Therapeutics’ peers have higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Viking Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viking Therapeutics N/A -330.42% -144.29%
Viking Therapeutics Competitors -5,082.56% -415.47% -40.45%

Volatility and Risk

Viking Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Viking Therapeutics’ peers have a beta of 5.91, indicating that their average stock price is 491% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Viking Therapeutics and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics 0 0 2 0 3.00
Viking Therapeutics Competitors 791 3134 11393 228 2.71

Viking Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 122.22%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.42%. Given Viking Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than its peers.


Viking Therapeutics peers beat Viking Therapeutics on 7 of the 12 factors compared.

About Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply